Genmab A/S: Business Overview, Financials & Competitive Analysis
Genmab A/S scores 7/10 on the AskCyborg Cyborg Score (Strong). Strong antibody technology platform with growing commercial portfolio and strategic partnerships positions Genmab well for sustainable oncology/autoimmune market growth despite near-term M&A execution risks. Genmab demonstrates strong execution with 8 approved antibody therapeutics, robust partnerships with pharmaceutical giants, and significant revenue growth. The Merus acquisition signals strategic ambition, though elevated.
What is Genmab A/S's industry? Genmab A/S (genmab.com) operates in Biotechnology - Therapeutic Antibodies & Oncology. AskCyborg classifies Genmab A/S under Biotechnology - Therapeutic Antibodies & Oncology in its company registry.
Genmab A/S is a Danish biotechnology company, founded in February 1999, specializing in development of antibody therapeutics for the treatment of cancer and other diseases. The company has 8 approved antibodies (monoc...
Cyborg Score thesis
Strong antibody technology platform with growing commercial portfolio and strategic partnerships positions Genmab well for...
Read the full analyst-debate transcript →Get the Latest Genmab A/S Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeGenmab A/S Overview
Pro stress-test →Genmab A/S is a Danish biotechnology company, founded in February 1999, specializing in development of antibody therapeutics for the treatment of cancer and other diseases. The company has 8 approved antibodies (monoclonal and bispecific) used in 8 marketed products, covering cancer indications and autoimmune diseases, with a strong pipeline addressing unmet medical needs across oncology and immunology.
Strategic Profile
Pro stress-test →Genmab harnesses advanced proprietary antibody platforms such as DuoBody, HexaBody, DuoHexaBody, and HexElect to create novel treatment solutions. The company has collaboration agreements with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, and others, enabling co-development and commercialization of breakthrough therapies. In September 2025, Genmab announced it would acquire Merus N.V.—a Dutch biotech company developing late-stage head and neck cancer drug—for ~$8 billion, signaling aggressive growth through strategic M&A.
Competitive Landscape
Pro stress-test →Genmab operates at the intersection of cutting-edge science and clinical innovation, addressing critical challenges in cancer treatment and autoimmune disorders. The company competes against established pharma (Roche, Novartis, J&J), emerging biotech immunology players, and next-gen antibody technology platforms. Genmab's differentiation lies in its multimodal antibody platforms and partner-assisted commercialization model rather than fully integrated development.
Industry Context
Genmab A/S operates in Biotechnology - Therapeutic Antibodies & Oncology.
Key facts
Founded: 1999 · Headquarters: Copenhagen, Denmark · Employees: 2,682 · Revenue: $3.4B · Market cap: $19.7B